- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00523159
IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable Disease (IMA901-202)
Phase 2, Randomized, Open Label, Multicenter Study of Intradermal IMA901 Plus GM-CSF With or Without Low Dose Cyclophosphamide Pre-treatment in Advanced Renal Cell Carcinoma Patients With Measurable Disease
This study was conducted in order to evaluate the efficacy and safety of the cancer vaccine IMA901 and GM-CSF as adjuvant in the treatment of advanced renal cell carcinoma.
Patients received vaccination with GM-CSF followed by IMA901 during the study period of 9 months. Patients received pre-treatment with a single i.v. infusion of cyclophosphamide prior to the first vaccination.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a multicenter, open label, randomized phase 2 study which investigated the effect of a second-line systemic treatment with IMA901 plus GM-CSF in RCC patients. Randomization was done according to a pre-treatment with low-dose cyclophosphamide (CY). Secondary endpoints comprised tumor response parameters.
The study population consisted of HLA-A*02-positive men or women with advanced RCC of the clear-cell type classified as having a favorable or intermediate risk after first-line systemic therapy for. Patients had to be aged 18 years or older, had at least have one measurable tumor lesion and had have received first-line tyrosine kinase inhibitor or cytokine systemic therapy for advanced disease, during or after which the patient had experienced disease progression.
Patients in both arms received a total of 17 vaccinations with GM-CSF followed by IMA901 during the 9 month treatment period.
At screening baseline tumor status was assessed by CT or MRI. During the study tumor assessments were performed every 6 weeks.
Immunomonitoring (T-cell responses to peptides contained in IMA901 and analysis of other immune cell populations that may influence T-cell responses), serum levels of antibodies and molecules with suspected influence on immune response were assessed on several occasions during the study.
Safety assessment comprised continuous adverse event reporting, regular physical examinations and regular assessments of vital signs, hematology, blood chemistry and urine. A 12-lead ECG was performed at screening and at the end of the study. Pregnancy testing was performed according to applicable legislation in the country where the trial was performed. At the very least, women of childbearing potential had have to undergo a pregnancy test during screening for the study, before the first dose was applied and at the end of the study.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Salzburg, Austria, 5020
- Medizinische Universität Salzburg - Universitätsklinik für Innere Medizin III
-
-
-
-
-
Sofia, Bulgaria, 1233
- Regional Oncodispensary with inpatient sector-Sofia District
-
Sofia, Bulgaria, 1233
- National Oncology Hospital - Urology
-
-
-
-
-
Berlin, Germany, 10117
- Charité Campus Mitte-Klinik für Urologie
-
Berlin, Germany, 12203
- Charité Campus Benjamin Franklin - Medizinische Klinik III
-
Chemnitz, Germany, 09130
- Zeisigwaldkliniken Bethanien Chemnitz GmbH
-
Essen, Germany, 45122
- Universitätsklinikum Essen
-
Frankfurt / Main, Germany, 60590
- Klinik der Johann-Wolfgang-Goethe-Universität
-
Hamburg, Germany, 20246
- Universitätsklinikum Hamburg-Eppendorf Onkologisches Zentrum (Onkologie / Hämatologie)
-
Heidelberg, Germany, 69120
- Universitätsklinikum Heidelberg - Klinik für Urologie
-
Lübeck, Germany, 23538
- Universitätsklinikum Schleswig Holstein - Campus Lübeck
-
Mainz, Germany, 55131
- Universitätsklinikum Mainz - 3. Medizinische Klinik
-
Munich, Germany, 81377
- Klinikum der Universität - München Großhadern
-
Planegg, Germany, 82152
- Urologische Klinik Dr. Castringius - München-Planegg
-
Tuebingen, Germany, 72076
- Universitätsklinikum Tübingen - Klinik für Urologie
-
Villingen-Schwenningen, Germany, 78050
- Schwarzwald-Baar-Klinik - Abt. Hämatologie und Onkologie
-
-
-
-
-
Balatonfüred, Hungary, 8230
- DRC Gyogyszervizsgalo Kozpont Kft
-
Budapest, Hungary, 1082
- Semmelweis Egyetem - Urológiai Klinika
-
Budapest, Hungary, 1106
- Bajcsy-Zsilinszky Kórház - Urológia Osztály
-
Budapest, Hungary, 1115
- Fövárosi Önk.Szt.Imre Kórház - Belgyógyászat-Kliniko-FFarmakológia
-
Budapest, Hungary, 1122
- Országos Onkológiai Intézet - Kemoterápia C osztály-Klinikofarmakológia
-
Debrecen, Hungary, 4012
- Debreceni Egyetem Orvos és Egeszsegtudomanyi Centrum
-
Debrecen, Hungary, 4043
- Hajdú-Bihar Megyei Önk. Kenézy Gyula Kórház/Urológia Osztály
-
Miskolc, Hungary, 3501
- BAZ megyei Kórház - Urológia Osztály
-
Pécs, Hungary, 7621
- Pécs Orvostudomanyi Egyetem - Urológiai Klinika
-
-
-
-
-
Lodz, Poland, 93509
- Klinika Chemioterapii Nowotworow - Uniwersytetu Medycznego
-
Warszawa, Poland, 00909
- Klinika Onkologii Wojskowego Institutu Medycznego
-
Wroclaw, Poland, 50-043
- Clinic of Urology and Urological Oncology Medica University Hospital
-
-
-
-
-
Bucharest, Romania, 022328
- Oncology Institute "Prof. Dr. Alexandru Trestioreanu"
-
Bucharest, Romania, 022328
- Oncology Institute - "Prof. Dr. Alexandru Trestioreanu"
-
Cluj-Napoca, Romania, 400015
- Oncology Institute "Prof. Dr. Ion Chiricuta"
-
Oradea, Romania, 4170167
- Clinical County Hospital Oradea
-
-
-
-
-
Bratislava, Slovakia, 83310
- National Cancer Institut - "Narodny onkologicky ustav"
-
Kosice, Slovakia, 04191
- Clinic of Radiotherapy and Oncology - East Slovak Oncology Institute
-
Martin, Slovakia, 03659
- Martin Faculty Hospital
-
Presov, Slovakia, 08181
- Department of Clinical Oncology - Faculty Hospital with Policlinic of J.A. Reiman
-
-
-
-
-
Barcelona, Spain, 08035
- Hospital Universitari Vall d'Hebrón
-
Madrid, Spain, 28035
- Hospital Universitario Puerta de Hierro
-
Madrid, Spain, 28041
- Hospital 12 de Octubre
-
Pamplona, Spain, 31008
- Clinica Universitaria de Navarra - Servicio de Oncologia
-
-
-
-
-
Geneva, Switzerland, 1211
- University Hospital - Medicine Oncology
-
-
-
-
-
Glasgow, United Kingdom, G11 6NT
- Beatson Oncology Centre
-
Manchester, United Kingdom, M20 4BX
- Christie Hospital NHS Trust, CRUK Department of Medical Onkology - Paterson Institute for Cancer Research
-
Surrey, United Kingdom, GU2 7WG
- University of Surrey - Postgraduate Medical School
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged at least 18 years
- HLA type: HLA-A*02-positive
- Histologically documented advanced clear-cell RCC
- Patients who have received first-line tyrosine kinase inhibitor or cytokine systemic therapy for advanced disease systematic therapy for advanced disease and must be candidates for second-line therapy (NOTE: in Germany and Austria only patients after first-line tyrosine kinase inhibitor failure will be included into the study)
- Patients having experienced documented tumor progression
- At least one unidimensional measurable target lesion
- Karnofsky Performance Status ≥ 80%
- Favorable or intermediate risk according to the 3-score MSKCC criteria.
- Able to understand the nature of the study and give written informed consent
- Willingness and ability to comply with the study protocol for the duration of the study
Exclusion Criteria:
- Poor risk according to the 3-score MSKCC criteria
- Immunosuppressive therapy within 4 weeks before study entry, e.g. corticosteroid treatment
- History of other malignant tumors, except non-melanoma-skin cancer or curatively excised cervical carcinoma in situ
- Presence of brain metastases on MRI or CT scan
- Patients with a history or evidence of systemic autoimmune disease
- Any vaccination in the two weeks before study entry
- Any planned prophylactic vaccination from study entry until the end of the induction period (5 weeks after the first vaccination)
- Known active hepatitis B or C infection
- Known HIV infection
- Any other infection with a biological agent that can cause a severe disease and poses a severe danger to lab personnel working on patient tissues.
Any of the following in the 4 weeks before study entry:
- Major surgery
- Anticancer treatments including (but not limited to) cytotoxic chemotherapy, radiotherapy, immunotherapy, hormone therapy, tyrosine kinase inhibitors, monoclonal antibodies
- Unresolved toxicity from prior anticancer treatments including (but not limited to) cytotoxic chemotherapy, hormone therapy, tyrosine kinase inhibitors, monoclonal antibodies, radiotherapy, or immunotherapy
- Received study drug within any clinical study
Any of the following abnormal laboratory values:
- Hematology: Hb < 9 g/dL; WBC < 3 x 109/L; neutrophils < 1.5 x 109/L; lymphocytes < 1.0 x 109/L; platelets < 100 x 109/L
- Liver function: serum bilirubin > 1.5 x upper normal limit (unless a history of Gilbert's disease); ALAT or ASAT > 3 x upper normal limit (>5 x upper normal limit if liver metastases are present)
- Renal function: serum creatinine > 200 µmol/L
Patients with other significant diseases currently uncontrolled by treatment which might interfere with study completion, for example:
- Heart failure or non compensated active heart disease
- Severe coronary heart disease, cardiac arrhythmia requiring medication, or uncontrolled hypertension
- Symptomatic neurotoxicity (motor or sensory) ≥ grade 2 National Cancer Institute - Common Toxicity Criteria (NCI-CTC).
- Severe pulmonary dysfunction
- Psychiatric disabilities, seizures or central nervous system disorders that may interfere with the ability to give informed consent or perform adequate follow-up in the investigator's opinion
- Active infections requiring oral or intravenous antibiotics
- Women or men who decline to practice a medically approved method of contraception
- Pregnancy or breastfeeding
- Any condition which in the judgment of the investigator would place the patient at undue risk or interfere with the results of the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: 1
Pre-treatment with a single low dose of Cyclophosphamide followed by IMA901 vaccination plus GM-CSF as adjuvant
|
a single i.v.
infusion of Cyclophosphamid and then patients received vaccination therapy with intradermal (i.d.) injections of GM-CSF followed by i.d.
injections of IMA901
|
Other: 2
No pre-treatment with Cyclophosphamide before vaccination with IMA901 and GM-CSF as adjuvant
|
Intradermal injection of GM-CSF followed by intradermal injection of IMA901
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Disease control rate
Time Frame: after 26 weeks
|
after 26 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Tumor response rates and SD rate
Time Frame: after 26 and 38 weeks
|
after 26 and 38 weeks
|
Duration of response
Time Frame: from the time response is first documented until the first date of recurrence or PD
|
from the time response is first documented until the first date of recurrence or PD
|
Time to response
Time Frame: From Visit c to PR or CR
|
From Visit c to PR or CR
|
TTP
Time Frame: From visit C to until tumor progression
|
From visit C to until tumor progression
|
PFS and OS
Time Frame: From visit C to tumor progression or death
|
From visit C to tumor progression or death
|
DCR
Time Frame: after 38 weeks on study
|
after 38 weeks on study
|
Immune response
Time Frame: Visit C, 1, 5, 6, 7, 10 and 14
|
Visit C, 1, 5, 6, 7, 10 and 14
|
Effect of cyclophosphamide pre-treatment on immune response
Time Frame: Visit C, 1, 5,6,7, 10, 14
|
Visit C, 1, 5,6,7, 10, 14
|
Safety
Time Frame: From inclusion on the study until 3 weeks after end of study visit
|
From inclusion on the study until 3 weeks after end of study visit
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Alexandra Kirner, PhD, Immatics Biotechnologies GmbH
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- EudraCT Nr: 2006-006370-25
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Cell Carcinoma
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Unresectable Renal Cell... and other conditionsUnited States
-
Australian and New Zealand Urogenital and Prostate...RecruitingRenal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Papillary Renal Cell Carcinoma Type 1 | Papillary Renal Cell Carcinoma Type 2 | Chromophobe Renal Cell Carcinoma | Xp11.2 Translocation-Related Renal Cell CarcinomaAustralia
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell CarcinomaUnited States
-
National Cancer Institute (NCI)Canadian Cancer Trials GroupActive, not recruitingUnresectable Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell Carcinoma | Metastatic Papillary Renal Cell Carcinoma | Locally Advanced Papillary Renal Cell CarcinomaUnited States, Canada
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell CarcinomaUnited States, Taiwan, Australia
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingChromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma | Fumarate Hydratase Deficient Renal Cell Carcinoma | Succinate Dehydrogenase Deficient Renal Cell Carcinoma | Collecting Duct Renal...United States
-
Australian and New Zealand Urogenital and Prostate...Bristol-Myers SquibbActive, not recruitingRenal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Papillary Renal Cell Carcinoma Type 1 | Papillary Renal Cell Carcinoma Type 2 | Chromophobe Renal Cell Carcinoma | Xp11 Translocation CarcinomaAustralia
-
Bradley A. McGregor, MDBristol-Myers Squibb; ExelixisRecruitingRenal Cell Carcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Collecting Duct Renal Cell Carcinoma | Translocation Renal Cell Carcinoma | Unresectable Advanced Renal Cell Carcinoma | Metastatic Ncc Renal Cell CarcinomaUnited States
-
Peloton Therapeutics, Inc.Active, not recruitingKidney Cancer | Renal Cell Carcinoma | Renal Cancer | Renal Cell Carcinoma (RCC) | Renal Cell Cancer Metastatic | Kidney | Clear Cell Renal Cell Carcinoma (ccRCC) | Renal Cell Carcinoma Recurrent | Renal Cell Cancer, RecurrentUnited States
-
AmgenCompletedRenal Cell Carcinoma | Clear Cell Renal Cell Carcinoma | Clear Cell Renal Carcinoma | Renal Cell AdenocarcinomaFrance, United States, Germany
Clinical Trials on Endoxana, IMA901, Leukine
-
Immatics Biotechnologies GmbHCompletedColorectal CarcinomaUnited Kingdom, Romania, Belgium, Bulgaria, Germany, Hungary, Latvia, Poland, Serbia
-
Immatics Biotechnologies GmbHCompletedMetastatic Renal Cell CarcinomaUnited States, France, Romania, United Kingdom, Italy, Russian Federation, Poland, Germany, Hungary, Netherlands, Norway
-
Children's Hospital Medical Center, CincinnatiGenzyme, a Sanofi Company; Virginia Commonwealth UniversityCompletedHereditary Pulmonary Alveolar ProteinosisUnited States
-
Genzyme, a Sanofi CompanyTerminatedLymphoma, FollicularUnited States, Puerto Rico
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast CancerUnited States
-
Galena Biopharma, Inc.CompletedBreast Cancer With Low to Intermediate HER2 ExpressionUnited States, United Kingdom, France, Israel, Germany, Canada, Russian Federation, Romania, Bulgaria, Czech Republic, Hungary, Poland, Ukraine
-
University Hospital, GhentFlanders Institute of BiotechnologyCompleted
-
Mark HallEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedCritical Injury (Trauma) in ChildrenUnited States
-
Massachusetts General HospitalBrain & Behavior Research Foundation; J Willard and Alice S. Marriott FoundationRecruitingBipolar Disorder | Depressive EpisodeUnited States